Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT ID: NCT05862337
Last Updated: 2023-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
480 participants
INTERVENTIONAL
2023-05-10
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adjuvant Therapy With Anlotinib for HCC
NCT04947371
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
NCT05975645
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
NCT04888546
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT03766776
TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
NCT05111366
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anlotinib hydrochloride capsules + Penpulimab injection
Anlotinib hydrochloride capsules + Penpulimab injection, 21 days as a treatment cycle.
Anlotinib hydrochloride capsules, Penpulimab injection
Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.
Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1).
Anlotinib hydrochloride capsules -matching placebo+ Penpulimab injection -matching placebo
Anlotinib hydrochloride capsules -matching placebo+ penpulimab injection -matching placebo, 21 days as a treatment cycle.
Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
placebo control, no active substance.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anlotinib hydrochloride capsules, Penpulimab injection
Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.
Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1).
Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
placebo control, no active substance.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or who meet the diagnostic criteria for Primary Liver Cancer 2022 or the American Association for the Study of Hepatology (AASLD) hepatocellular carcinoma.
* Subjects who received radical excision or ablation (Radio Frequency Ablation (RFA) or Microwave Ablation (MWA) only) within 4 to 12 weeks prior to randomization (multiple modalities or combined or multiple treatments are not acceptable).
* No major vena portae 3 (Vp3) or vena portae 4 (Vp4) in the portal vein or any level of vascular invasion in the hepatic vein or inferior vena cava.
* No extrahepatic metastasis.
* High risk factors for recurrence after radical resection or complete ablation.
* Complete recovery from surgical resection or ablation within 4 weeks before randomization.
Exclusion Criteria
* Evidence of residual, recurrent, or metastatic disease at randomization.
* More than one surgical treatment for hepatocellular carcinoma; Received more than 1 prophylactic Transcatheter Arterial Chemoembolization (TACE) treatment after surgery; or received Hepatic Artery Infusion Chemotherapy (HAIC) therapy after surgery.
* Previous use of antiangiogenic drugs or PD-1, Programmed Cell Death-Ligand 1 (PD-L1) and other related immunotherapy drugs or systemic chemotherapy drugs.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Anhui Provincial Hospital
Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Beijing Friendship hospital of Capital Medical University
Beijing, Beijing Municipality, China
Beijing YouAn Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical
Fuzhou, Fujian, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
Lanzhou University First Hospital
Lanzhou, Gansu, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
Guangdong People's Hospital
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China
Guizhou Provincial People'S Hospital
Guiyang, Guizhou, China
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Affiliated Hospital Of Zunyi Medical University
Zunyi, Guizhou, China
Hainan Provincial People's Hospital
Haikou, Hainan, China
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
The Third Xiang Ya Hospital of Central South University
Changsha, Hunan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Chifeng Municipal Hospital
Chifeng, Inner Mongolia, China
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
Jiangsu Province People's Hospital
Nanjing, Jiangsu, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Nantong Tumor Hospital
Nantong, Jiangsu, China
Ganzhou People's Hospital
Ganzhou, Jiangxi, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jilin Cancer Hospital
Changchun, Jilin, China
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
The Sixth People's Hospital of Shen Yang
Shenyang, Liaoning, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Binzhou Medical University Hospital
Binzhou, Shandong, China
Shandong Cancer Hospital
Jinan, Shandong, China
The First Affiliated Hospital of Naval Medical University
Shanghai, Shanghai Municipality, China
Third Affiliated Hospital of Naval Medical University
Shanghai, Shanghai Municipality, China
Baoji Central Hospital
Baoji, Shanxi, China
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, China
First Affiliated Hospital of Xian Jiaotong University
Xi’an, Shanxi, China
Xi'an International Medical Center Hospital
Xi’an, Shanxi, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Affiliated Hospital Of North Sichuan Medical College
Nanchong, Sichuan, China
Tianjin Third Central Hospital
Tianjin, Tianjin Municipality, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Sir Run Run Shaw Hospital Zhetiang University School of Medicine
Hangzhou, Zhejiang, China
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China
Shaoxing People's Hospital
Shaoxing, Zhejiang, China
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yonghong Zhang, Doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALTN-AK105-III-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.